Immutep Received ~A$1.13M R&D Tax Incentive
Portfolio Pulse from Charles Gross
Immutep Limited has received a A$1,134,882 cash rebate from the Australian Federal Government's R&D tax incentive program. The rebate is for expenditure incurred on eligible R&D activities conducted in the 2022 fiscal year, mainly related to the Company's TACTI-002 and TACTI-003 clinical study using its lead compound eftilagimod alpha. The company will use the non-dilutive funding towards furthering its current active clinical trial programs.
October 25, 2023 | 8:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep Limited has received a significant cash rebate from the Australian Federal Government's R&D tax incentive program. This non-dilutive funding will be used to further its current active clinical trial programs, potentially accelerating the development of its lead compound.
The receipt of the R&D tax incentive provides Immutep with additional non-dilutive funding, which is a positive development for the company. This funding will be used to further its clinical trial programs, potentially accelerating the development and eventual commercialization of its lead compound. This could have a positive impact on the company's future revenues and profitability, which would likely be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100